Hepatitis C treatment: Shorter and better?

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 1, 2007, Pages 118-124

  de Araújo, Evaldo Stanislau Affonso ^a   Courtoké, Cláudia ^a   Barone, Antonio Alci ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HCV; Interferon; Viral kinetics

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

DISEASE COURSE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MICROBIAL KINETICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVIEW; SHORT COURSE THERAPY; TREATMENT FAILURE; VIREMIA; VIRUS LOAD; VIRUS PARTICLE; VIRUS VIRULENCE;

EID: 34347381999     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702007000100026     Document Type: Review

References (25)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
2. Araujo E.S.A., Silveira O.S. Hepatites na cidade de São Paulo in DST/Aids, a nova cara da luta contra a epidemia na cidade de São Paulo. 2003:55-68.
3. Nguyen T.T., Sedghi-Vaziri A., Wlkes L.B., et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. Journal of Viral Hepatitis 1996;3(2):75-8.
4. Pawlotsky J.M. Current and Future Concepts in Hepatitis C Therapy. Seminars in Liver Disease 2005;25:72-83.
5. Layden J.E., Layden T.J. How can Mathematics help us understand HCV? [Editorial]. Gastroenterology 2001;120(6):1546-9.
6. Tang K.H., Herrmann E., Cooksley H., et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Journal of Hepatology 2006;43:776-82.
7. Ji X., Cheung R., Cooper S., et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003;37:610-21.
8. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72.
9. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282(5386):103-7.
10. Pham T.N.Q., Macparland S.A., Mulrooney P.M., et al. Hepatitis C Virus Persistence after spontaneous or treatmentinduced resolution of Hepatitis C. Journal of Virology 2004;78(11):5867-74.
11. Feld J.j., Liang T.J. HCV Persistence: cure is still a four letter word. Hepatology 2005;41:23-5.
12. Poynard T. Management protocols in chronic hepatitis C in Hepatitis C and B Management and Treatment, Second Edition, Taylor and Frances Ed, 2005:19-34.
13. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. Journal of Hepatology 2005;43:425-33.
14. Soriano V. Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates. Journal of Hepatology 2006;44:S44-S8.
15. Araujo E.S.A., Neumann A.U., Courtouke C., et al. Early HCV kinetics predict sustained virological response to treatment with Peginterferon A2A and Ribavirin in Brazilian HIV/HCV co-infected patients. [P 38]. Abstracts book of the 12th International Symposium on Hepatitis C and Related Viruses; 2005 Oct 2-6; Montreal, Canada. p.94.
16. Mangia A., Santoro R., Minerva N., et al Peginterferon Alfa 2b and Ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3, The New England Journal of Medicine 2005;325:2609-17.
17. Zeuzem S., Buti M., Ferenci P., et al Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia, Journal of Hepatology 2006;44:97-103.
18. Dalgard O., Bjoro K., Hellum K.B., et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
19. Craxi A., Cammà C. Treating patients with HCV genotype 1 and low viraemia: More than meets the eye. Journal of Hepatology 2006; 44:4-7.
20. Lutchman G., Hoofnagle J.H. Viral kinetics in hepatitis C. Hepatology 2003;37(6):1257-9.
21. Foster G.R. Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics 2004;20(8):825-30.
22. Taylor M., Schaley J., Edenberg H., et al. Distinct differences in gene response between patients resistant to Interferon/Ribavirin therapy and those showing early vírus clearance [Oral Presentation 1]. Abstract book of the 11th International Symposium on Hepatitis C Vírus and Related Viruses; 2004; Heidelberg, Germany. p.5.
23. Silva M., Poo J., Wagner F., et al. A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology 2006;45:204-13.
24. Dhalluin C., Ross A., Huber W., et al. Structural, Kinetic, and Thermodynamic analysis of the binding of the 40 Kda Peg-Interferon-α2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjugate Chem 2005;16:518-27.
25. Manns M., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. GUT 2006;55:1350-9.